Table 1

Characteristics of studied subjects at blood sampling

HD (n=28)Active GCA (n=14)Inactive GCA (n=27)P†
Age (years)—median (IQR)61.8 (58.9–76.8)68.3 (63.3–77.7)69.3 (61.5–77.1)0.3548 (ns)
Sex, female—no (%)15 (53.6)8 (57.1)16 (59.2)0.9122 (ns)
N.European ethnicity—no (%)27 (96.4)13 (92.3)23 (85.2)0.3260 (ns)
Disease duration (years)—median (IQR)1.1 (0.1–4.1)3.5 (0.8–6.2)0.1446 (ns)
CRP (mg/L)—median (IQR)30.9 (11.1–60.6)1 (0.5–2.6)<0.001‡
ESR 1 hour (mm)—median (IQR)45 (33–80.5)8 (5–22)<0.001‡
Relapsed cases—no (%)8 (57.1)
TCZ—no (%)12 (44.4)
Duration of TCZ treatment, median (years)—median (IQR)1 (0.4–2.8)
Corticosteroids as monotherapy—no (%)3 (21.4)8 (29.6)0.7186 (ns)
Prednisolone or prednisolone equivalent dose (mg)—median (IQR)0 (0–5)2.5 (0–5)0.2040 (ns)
MTX—no (%)7 (25.9)
LFN—no (%)1 (7.1)1 (3.7)
  • *P<0.05.

  • †P<0.001.

  • ‡ns, non-significant.

  • CRP, C reactive protein; GCA, giant cell arteritis; HD, healthy blood donor; LFN, leflunomide; MTX, methotrexate; ns, non-significant; TCZ, tocilizumab.